Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K
Department of Immunology, Kyushu University, Fukuoka, Japan.
J Immunol. 1990 Sep 1;145(5):1303-10.
The cellular basis of the transplantation tolerance in a model system of BALB/c (Mls-1b) mice rendered cyclophosphamide (CP)-induced tolerant to DBA/2 (Mls-1a) skin allograft was investigated by assessing V beta 6+ T cells. From our results, three major mechanisms that are essential to the CP-induced skin allograft tolerance were sequentially elucidated. The first mechanism was destruction of donor-Ag-stimulated T cells in the periphery by CP treatment. The second mechanism was intrathymic clonal deletion of donor-reactive T cells, such as V beta 6+ T cells, correlating strongly with intrathymic mixed chimerism. The clonal deletion, however, was not always essential for the maintenance of the skin allografts, because DBA/2 skin survived even after the clonal deletion terminated and V beta 6+ T cells reappeared in the periphery of the recipient BALB/c mice. The third mechanism was generation of tolerogen-specific suppressor T cells, especially in the late stage of the tolerance. In contrast, the clonal anergy that is evidenced by the specific suppression of mixed lymphocyte reaction in the recipient BALB/c mice after injecting with DBA/2 spleen cells alone was not considered as a significant mechanism in prolonging skin allograft survival because such anergic mice showed accelerated rejection of the skin allografts. These results may suggest practical hierarchy of the mechanisms of CP-induced allograft tolerance.
通过评估Vβ6 + T细胞,研究了环磷酰胺(CP)诱导的BALB / c(Mls-1b)小鼠对DBA / 2(Mls-1a)皮肤同种异体移植产生耐受的模型系统中移植耐受的细胞基础。根据我们的结果,依次阐明了CP诱导皮肤同种异体移植耐受所必需的三种主要机制。第一种机制是通过CP处理破坏外周血中供体抗原刺激的T细胞。第二种机制是胸腺内供体反应性T细胞的克隆清除,例如Vβ6 + T细胞,这与胸腺内混合嵌合体密切相关。然而,克隆清除对于维持皮肤同种异体移植并不总是必不可少的,因为即使克隆清除终止且Vβ6 + T细胞在受体BALB / c小鼠外周血中重新出现后,DBA / 2皮肤仍能存活。第三种机制是耐受原特异性抑制性T细胞的产生,尤其是在耐受的后期。相比之下,仅在注射DBA / 2脾细胞后受体BALB / c小鼠中混合淋巴细胞反应的特异性抑制所证明的克隆无能,在延长皮肤同种异体移植存活时间方面不被认为是一种重要机制,因为这种无能小鼠表现出皮肤同种异体移植的加速排斥。这些结果可能提示了CP诱导同种异体移植耐受机制的实际层次结构。